• UCLA Health
  • myUCLAhealth
  • School of Medicine
U Magazine

U Magazine

U Magazine
  • Home
  • Current Issue
  • Centennial Campaign for UCLA Issue
  • Browse U Magazine
  • Letters to the Editor
  • Subscribe
  • Contact
  • UCLA Health
  • myUCLAhealth
  • School of Medicine

U Magazine

Browse U Magazine

  1. Home
  2. Browse U Magazine
Share this
The Cutting Edge

Stem-cell Therapy Holds Promise for Eliminating HIV Infection

  T cells to locate and kill HIV-infected cells  
 

UCLA scientists are engineering T cells to locate and kill HIV-infected cells.
Graphic: Mirabai Vogt

Scientists at the UCLA Eli & Edythe Broad Center of Regenerative Medicine & Stem Cell Research are one step closer to engineering a tool to arm the body’s immune system to fight — and win — against HIV. The new technique harnesses the regenerative capacity of stem cells to generate an immune response to the virus.

“We hope this approach can one day allow HIV-positive individuals to reduce, or even stop, their current HIV drug regimen and clear the virus from the body altogether,” says Scott Kitchen, PhD, associate professor of medicine in the Division of Hematology and Oncology. “We also think this approach could possibly be extended to other diseases.”

Dr. Kitchen and his colleagues are the first to report the use of an engineered molecule called a chimeric antigen receptor (CAR) in blood-forming stem cells. The researchers inserted a gene for a CAR into blood-forming stem cells in the lab, which then were transplanted into genetically engineered HIV-infected mice. The researchers found that the CAR-carrying blood stem cells successfully turned into functional T cells that could kill HIV-infected cells in the mice. The result was an 80-to-95 percent decrease in HIV levels, strongly suggesting that stem-cell-based gene therapy with a CAR may be a feasible and effective treatment for chronic HIV infection in humans.

“Despite the increased scientific understanding of HIV and better prevention and treatment with available drugs, a majority of the 35-million people living with HIV, and millions more at risk of infection, do not have adequate access to prevention and treatment, and there is still no practical cure,” says Jerome Zack, PhD, co-director of the UCLA AIDS Institute and associate director of the UCLA Broad Stem Cell Research Center. “With the CAR approach, we aim to change that.”

Previous studies by Drs. Kitchen and Zack demonstrated similar results with other T-cell receptors, although it is known that HIV could mutate away from those receptors. Another shortcoming of T-cell receptors used in earlier clinical studies was that they could not be universally used in patients because they would have to be individually matched to patients — in the same way organs are matched to transplant recipients.

Dr. Kitchen says the CAR approach is more flexible, and potentially more effective, because it could theoretically be employed in anyone. If further testing continues to show promise, the researchers hope a treatment based on their approach could be brought to human clinical trials within five-to-10 years.

“Engineering Cellular Resistance to HIV-1 Infection In Vivo Using a Dual Therapeutic Lentiviral Vector,” Molecular Therapy, April 14, 2015


Previous
Portable Finger Probe Measures Liver Function in Potential Donors
Next
REM Sleep Helps Brain Capture Snapshots of Dream Images


YOU ARE VIEWING

Fall 2015

Fall 2015
E-Brochure
Printable PDF
IN THIS ISSUE
  • We Are the World
  • Camp Leg Power Propels Kids with Cerebral Palsy Forward
  • Portable Finger Probe Measures Liver Function in Potential Donors
  • Stem-cell Therapy Holds Promise for Eliminating HIV Infection
  • REM Sleep Helps Brain Capture Snapshots of Dream Images
  • Germline Cells Shown to be Vulnerable during Pregnancy
  • New Study Opens Window on Mutations in Genetic Architecture of Schizophrenics
  • How Molecular Rules Govern Autoimmune Disorders
  • Predicting Response to Treatment for Obsessive-Compulsive Disorder
  • Why Children’s Recovery Times Vary after Traumatic Brain Injury
  • Potentially Effective Treatment for Meth Addiction
  • Protein that Helps Suppress Cancer Fades as We Age
  • Patient First to Bridge from Experimental Total Artificial Heart to Transplant
  • UCLA Community Based Learning: Bridging the Transition from Youth to Adulthood
  • Get Social
  • The End of Darkness
  • Medicine 2.0
  • White Knight
  • Awards, Honors & Grants
  • In Memoriam
  • Postcard from Malawi
  • In Her Own Words: Lynn L. Huang, MD ’07
  • The Business of Medical Innovation
  • Tribute to a Mentor and Friend
  • Kaleidoscope Ball Highlights Artistic Variety
  • Landmark Gift Paves the Way for Breakthroughs
  • The UCLA Today’s and Tomorrow’s Children’s Fund Names New Awardees
  • Golden Portal Fundraiser Joins Movies, Medicine and Technology
  • Widening the Circle of Giving
  • UCLA Names Landmark New Medical-Education Building Geffen Hall
  • Gifts
  • In Memoriam
  • Good Afternoon, Mrs. Gates
Like Us on Facebook Follow Us on Twitter Subscribe to Our Videos on YouTube Follow us on Instagram Connect with Us on LinkedIn Follow us on Pinterest
UCLA Health hospitals ranked best hospitals by U.S. News & World Report
  • UCLA Health
  • Find a Doctor
  • School of Medicine
  • School of Nursing
  • UCLA Campus
  • Directory
  • Newsroom
  • Subscribe
  • Patient Stories
  • Giving
  • Careers
  • Volunteer
  • International Services
  • Privacy Practices
  • Nondiscrimination
  • Billing
  • Health Plans
  • Emergency
  • Report Broken Links
  • Terms of Use
  • 1-310-825-2631
  • Maps & Directions
  • Contact Us
  • Your Feedback
  • Report Misconduct
  • Get Social
  • Sitemap
Like Us on Facebook Follow Us on Twitter Subscribe to Our Videos on YouTube Follow us on Instagram Connect with Us on LinkedIn Follow us on Pinterest

Sign in to myUCLAhealth

Learn more about myUCLAhealth